| 2015-11-30 |
Karyopharm Therapeutics Inc |
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Hematologic Malignancies karyopharm.com ↗ |
| 2015-06-01 |
Karyopharm Therapeutics Inc |
Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Recurrent Glioblastoma and Advanced Sarcomas at 2015 ASCO Annual Meeting karyopharm.com ↗ |
| 2015-05-30 |
Karyopharm Therapeutics Inc |
Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Heavily Pretreated Gynecological Cancers and Asian Patients With Advanced Malignancies at 2015 ASCO Annual Meeting karyopharm.com ↗ |
| 2015-05-28 |
Karyopharm Therapeutics Inc |
Karyopharm Initiates STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma karyopharm.com ↗ |
| 2015-05-27 |
Karyopharm Therapeutics Inc |
Karyopharm to Present Clinical Data Update for Selinexor (KPT-330) in Solid Tumors karyopharm.com ↗ |
| 2015-04-13 |
Karyopharm Therapeutics Inc |
Karyopharm Granted U.S. Composition-of-Matter Patent for Selinexor (KPT-330) karyopharm.com ↗ |
| 2015-01-08 |
Karyopharm Therapeutics Inc |
Karyopharm Announces Orphan Designation Granted by FDA for Selinexor (KPT-330) in Multiple Myeloma karyopharm.com ↗ |
| 2014-12-11 |
Karyopharm Therapeutics Inc |
Karyopharm Initiates Third Registration-Directed Clinical Trial of Oral Selinexor (KPT-330) karyopharm.com ↗ |
| 2014-12-08 |
Karyopharm Therapeutics Inc |
Karyopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting karyopharm.com ↗ |
| 2014-12-08 |
Karyopharm Therapeutics Inc |
Karyopharm Presents Positive Clinical Data for Selinexor (KPT-330) in NHL Patients at ASH 2014 Annual Meeting karyopharm.com ↗ |
| 2014-12-01 |
Karyopharm Therapeutics Inc |
Karyopharm Announces Additional Orphan Designations Granted for Selinexor (KPT-330) by European Commission karyopharm.com ↗ |
| 2014-11-10 |
Karyopharm Therapeutics Inc |
Karyopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With Richter's Transformation karyopharm.com ↗ |
| 2014-09-29 |
Karyopharm Therapeutics Inc |
Karyopharm Announces Clinical Data for Selinexor (KPT-330) in Advanced Solid Tumors karyopharm.com ↗ |
| 2014-09-25 |
Karyopharm Therapeutics Inc |
Karyopharm to Host Conference Call to Discuss Selinexor (KPT-330) Data Presented at ESMO 2014 karyopharm.com ↗ |
| 2014-06-24 |
Karyopharm Therapeutics Inc |
Karyopharm Initiates Registration-Directed, Randomized Study of Selinexor (KPT-330) in Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) karyopharm.com ↗ |
| 2014-06-09 |
Karyopharm Therapeutics Inc |
Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study) karyopharm.com ↗ |
| 2014-04-29 |
Karyopharm Therapeutics Inc |
Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING Study) karyopharm.com ↗ |
| 2014-04-24 |
Karyopharm Therapeutics Inc |
Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Advanced Gynecologic Malignancies (SIGN Study) karyopharm.com ↗ |
| 2014-04-21 |
Karyopharm Therapeutics Inc |
Karyopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) karyopharm.com ↗ |
| 2014-04-15 |
Karyopharm Therapeutics Inc |
Karyopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen(R)) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML) karyopharm.com ↗ |
| 2014-02-27 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore karyopharm.com ↗ |
| 2014-01-22 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics Presents Clinical Data on Selinexor (KPT-330) in Colorectal Cancer From Ongoing Phase 1 Study and Preclinical Data on Novel PAK4 Inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium karyopharm.com ↗ |
| 2013-08-07 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research Conferences karyopharm.com ↗ |
| 2013-06-02 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual Meeting karyopharm.com ↗ |
| 2013-05-28 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress karyopharm.com ↗ |
| 2013-05-15 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual Meeting karyopharm.com ↗ |
| 2013-01-17 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE) karyopharm.com ↗ |
| 2012-07-25 |
Karyopharm Therapeutics Inc |
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers karyopharm.com ↗ |
|